Drug eluting balloon
The present invention is an inflatable balloon which is enclosed by an expandable cover which becomes increasingly porous/permeable during expansion. The balloon is coated or enclosed with a matrix which contains a pharmaceutically active agent. During expansion of the balloon, the pharmaceutically active agent is released or extruded through the expandable cover into a body cavity such as an artery or vein. The present invention also provides for a method of treating a disease or condition by delivering the inflatable balloon to a particular body cavity.
1. A medical device, comprising a balloon, a coating and an expandable polymer cover, wherein the coating comprises a biocompatible matrix, wherein the balloon in a non-inflated state comprises a plurality of pleats, wherein the biocompatible matrix is disposed between the balloon and the expandable polymer cover, wherein the expandable polymer cover encloses the non-inflated balloon and the biocompatible matrix, and wherein the permeability and/or porosity of the expandable polymer cover in an expanded state ranges from 20% to 400% greater as compared with the permeability and/or porosity of the expandable polymer cover in an unexpanded state, wherein the biocompatible matrix comprises one or more macrolide drugs in a crystalline form and two thin films having a thickness ranging from 3 μm to 250 μm, and wherein the macrolide drug is released into an aqueous environment for at least 25 days after the balloon is inflated.
2. The medical device of claim 1 , wherein the thin film comprises a polysaccharide polymer.
3. The medical device of claim 2 , wherein the polysaccharide polymer is pullulan.
4. The medical device of claim 1 , wherein the one or more macrolide drugs are encapsulated in a microsphere, liposome, nanoparticle, nanogel or mixtures thereof.
5. The medical device of claim 4 , wherein the microsphere or nanoparticle is a lipid particle or lipid vesicle.
6. The medical device of claim 4 , wherein the microsphere or nanoparticle is a PLGA (poly(lactic-co-glycolic acid)) particle.
7. The medical device of claim 1 , wherein the one or more macrolide drugs comprise everolimus, tacrolimus, zotarolimus, biolimus, rapamycin or mixtures thereof.